Drug intelligence / Profile preview

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(2-pyridinyl)phenyl]-1,3-oxazol-2-amine

Development stage
Unknown
Modality
Small Molecules
01

Overview

N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(2-pyridinyl)phenyl]-1,3-oxazol-2-amine is a synthetic small molecule classified as a phenylpyridine derivative. It is listed in chemical and pharmaceutical databases as an experimental compound. The compound has demonstrated inhibitory activity against vascular endothelial growth factor receptor 2 (VEGFR 2), with an IC50 of 17 nM reported in binding assays. Its primary mechanism of action is presumed to be the inhibition of VEGFR 2 kinase activity, which may have implications for antiangiogenic or antineoplastic research applications[1][2]. There are no approved therapeutic indications or marketed products containing this molecule.

Other names
N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINEN-[5-(ethanesulfonyl)-2-methoxyphenyl]-5-[3-(pyridin-2-yl)phenyl]-1,3-oxazol-2-aminen-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-(3-pyridin-2-ylphenyl)-1,3-oxazol-2-amine
02

Targets

CDK2 (Cyclin-dependent kinase 2)CDK4 (Cyclin-dependent kinase 4)VEGFR2 (Vascular endothelial growth factor receptor 2)

Beyond the preview

Go deeper on N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(2-pyridinyl)phenyl]-1,3-oxazol-2-amine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-[5-(ethylsulfonyl)-2-methoxyphenyl]-5-[3-(2-pyridinyl)phenyl]-1,3-oxazol-2-amine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call